Hawkins, Lindsay M <br/><br/>
Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.  [electronic resource] 

 -  Pediatric research  Mar 2005 
 - 430-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0031-3998 
<br/><br/><label>Standard No.: </label>10.1203/01.PDR.0000153871.45184.19  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-Bacterial Agents--metabolism<br/>Antineoplastic Agents--metabolism<br/>Apoptosis--drug effects<br/>Benzamides<br/>Benzoquinones<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Child<br/>Drug Resistance, Neoplasm<br/>Drug Therapy, Combination<br/>Genes, abl<br/>Humans<br/>Imatinib Mesylate<br/>Lactams, Macrocyclic<br/>Piperazines--metabolism<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Protein Kinase Inhibitors--metabolism<br/>Pyrimidines--metabolism<br/>Rifabutin--analogs & derivatives